420 with CNW – Does Federal Cannabis Legalization Now Stand a Chance After Democrats’ Midterm Wins?

Democrats’ victories in the midterm elections have renewed expectations that Congress could make progress on federal cannabis reform, with the party preparing to take control of both chambers.

The Democratic-led House has previously approved federal legalization proposals twice, with the most recent vote taking place in 2022. Efforts in the Senate, however, have faced greater resistance. Under Senate rules, most legislation requires 60 votes to overcome a filibuster, making it difficult to advance even measures with support from members of both parties, including proposals to improve banking access for marijuana companies.

The debate has also changed since Democrats last held congressional majorities. More states have adopted marijuana legalization policies, while the Trump administration has begun pursuing a narrower change to marijuana classification under the CSA.

Advocates are now urging the incoming Senate majority leader and House speaker to consider broader reform rather than rely solely on administrative changes. Both lawmakers have previously backed legislation to remove marijuana from the CSA. Their proposals have included the 2019 Marijuana Freedom and Opportunity Act and subsequent efforts to establish a regulated national cannabis market.

Democrats could secure up to 56 Senate seats, with 54 already confirmed. Two contests remain unresolved and available results suggest they could be won by Democrats. Passing comprehensive reform would therefore require cooperation from several Republican senators.

NORML’s Morgan Fox said roughly 66 percent of U.S. adults support ending prohibition. He urged Democratic leaders to respond to public opinion by pursuing legislation with bipartisan backing.

Fox also cautioned that federal rescheduling remains incomplete. Although medical cannabis has been moved to Schedule 3, broader changes covering recreational cannabis remain uncertain because of ongoing proceedings involving the DEA.

Drug Policy Alliance representative Cat Packer similarly argued that rescheduling alone would not address the consequences of federal criminalization. She called for legislation protecting individuals, improving public health safeguards, and creating a regulatory framework covering marijuana and hemp.

Meanwhile, National Cannabis Industry Association board chair Adam Rosenberg said Democratic control could help advance banking access, tax changes, and clearer rules for state-licensed businesses. He noted that the industry generates over $29 billion annually and supports over 400,000 workers.

Despite growing industry engagement, Republican congressional leaders have generally resisted legalization proposals. Political contributions from cannabis executives to Democratic fundraising groups have also drawn attention, alongside spending by a pro-Trump political committee supporting Republican lawmakers, including some who have opposed cannabis reform.

For firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) that have for long participated in efforts to reform marijuana laws at state level, the excitement about Democratic control of Congress may be premature for the industry since Trump holds veto powers and any bill passed could be stopped in its tracks by opposition from the president.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Federal Prosecutors Indict Virginia Senator on Illegal Cannabis Enterprise Charges

Federal prosecutors have charged Virginia State Senator Louise Lucas and 6 other people in connection with an investigation into two Portsmouth cannabis businesses that authorities say were used to distribute marijuana illegally.

The case follows federal raids conducted in May this year at the two cannabis outlets. The DOJ said that FBI agents executing a search warrant found firearms and cannabis at both properties.

On October 22, prosecutors announced an eight-count indictment accusing the seven defendants of operating a criminal enterprise that allegedly sold recreational cannabis while presenting the businesses as lawful CBD and hemp retailers.

Federal officials said the investigation had been underway for several years. U.S. AG Todd Blanche stated that investigators had developed the case over an extended period based on evidence and information gathered during the probe.

Director of the FBI Kash Patel alleged that Lucas earned millions from the operation. He said investigators believe she obtained almost $5 million in what prosecutors characterize as illicit proceeds over nearly five years.

Prosecutors also cited a February conversation in which Lucas allegedly discussed the business in terms of building wealth, saying it represented a final opportunity to secure her family’s financial future.

Lucas, who entered the Virginia Senate in 1992 and became Senate president pro tempore in 2020, rejected the allegations publicly. In a post on X, she said she would not be pressured into backing down.

Virginia law distinguishes hemp products from marijuana, and recreational cannabis sales remain prohibited in the state. Licensed medical marijuana businesses are permitted, while lawmakers have separately taken steps toward establishing a broader adult-use market. That system is not scheduled to begin retail operations until next July. Cannabis also remains prohibited under federal law.

The DOJ says Lucas and one of her daughters opened The Cannabis Outlet in 2021. Another daughter and Lucas’ grandson allegedly handled distribution activities at the store.

Prosecutors say both businesses were connected through VA Freedom Life, a company Lucas helped establish in 2019 with Carlton Upton Jr. Lucas later identified herself as the company’s CEO and president.

Lucas faces five of the charges, including drug distribution conspiracy, racketeering, money laundering, and maintaining premises connected to drug activity.

The indictment has also raised questions about Lucas’ future in the state Senate. Gov. Abigail Spanberger said Lucas and her relatives should be allowed to defend themselves while expressing concern about the timing and broader implications of the federal case. House Speaker Don Scott similarly criticized what he described as political interference by the Trump administration, while acknowledging the seriousness of the accusations.

The case highlights the continuing conflict between state efforts to regulate cannabis and federal prohibition, leaving businesses operating in the sector exposed to significant legal risks.

The marijuana industry, including operators like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), will be following how this case proceeds and the rulings made.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – DOJ, Marijuana Prohibitionists Reach Agreement on Scheduling Court Briefings

The Justice Department (DOJ) and organizations challenging the federal government’s effort to loosen cannabis restrictions have submitted a joint proposal for moving their legal battle forward. 

In a filing submitted Friday to the U.S. Court of Appeals for the DC Circuit, the parties outlined a schedule that would complete written arguments by February 2027 and potentially allow judges to hear oral arguments before the court goes into recess. 

The consolidated litigation involves three separate challenges to the rescheduling of cannabis from Schedule 1 to Schedule 3 of the CSA. The cases were brought by the NDASA and SAM, a coalition that includes cannabis opponents, and medical professionals, and attorneys general from Nebraska and Indiana. 

Under the agreement, the eleven petitioners would combine their arguments into one opening brief and one reply. The proposed timeline calls for the main petitioners’ brief to be filed Nov. 24, followed by supporting briefs from outside parties on Dec. 1. The government would respond by Jan. 13 next year, with additional supporting briefs due Jan. 20. Petitioners would then submit their reply by Feb. 5, followed by the joint appendix and final briefs later that month. 

The parties said the schedule gives challengers additional time to prepare combined filings while allowing government attorneys more time because the response period overlaps with several holidays. They also cited previously scheduled international travel involving government counsel. 

The filing asks the appeals court to hear arguments as soon as practical after briefing concludes. The parties also want permission to exceed the court’s usual word limits, citing the number of issues involved and questions surrounding whether the challengers have legal standing. 

The latest development follows the court’s rejection last month of a request by MMJ and NDASA to halt the reclassification process while the lawsuits proceed. The challengers argued that reclassification could expand cannabis use and create broader public health concerns. 

The DOJ countered that the groups have financial interests tied to keeping cannabis in the most restrictive federal category and questioned whether they are appropriate parties to challenge the policy. 

Additionally, the court declined to let two medical cannabis companies formally intervene on the government’s side, although they were permitted to participate by submitting friend-of-the-court briefs. 

Separately, proceedings before a DEA administrative judge have focused on the broader rescheduling proposal. The DEA has argued that cannabis no longer meets the criteria for Schedule 1 as it has recognized medical applications and can be used safely under a physician’s supervision. 

The DEA has also relied on a review by the DHHS, which recommended moving cannabis to Schedule 3. The agency said the evidence better places cannabis alongside Schedule 3 substances based on abuse and dependence characteristics. 

Opponents dispute that conclusion, challenging the federal government’s updated method for determining accepted medical use and warning about potential effects on workplace drug testing. 

The administrative judge will ultimately issue a recommendation, while the DEA administrator will make the final determination. The marijuana industry, including businesses like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), will be watching how the rescheduling process moves through the different steps before a final ruling is made. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Federal Survey Reveals Continuing Decline of Teenage Marijuana Use

Recent figures released by the Substance Abuse and Mental Health Services Administration (SAMHSA) indicate that cannabis use among young adults and teenagers in the United States continues to move downward, extending a trend that has been observed over the past several years. 

The latest annual findings show declines in both monthly and yearly marijuana consumption among people aged 12 to 17, as well as those between 18 and 25. The report also points to fewer adolescents trying cannabis for the first time, suggesting that initiation rates are continuing to decrease. 

Among teenagers, the share of respondents who said they had used cannabis within the previous month dropped by 22% over a three-year period (2022-2025). During the same period, reported use over the previous year declined by 25%. Officials noted that first-time experimentation with marijuana has also become less common within this age group. 

Young adults experienced a similar, although less pronounced, decline. According to the report, past-month marijuana use among individuals aged 18 to 25 fell by 10% over the three-year period. Annual use also decreased, with the proportion of respondents reporting marijuana consumption during the previous year dropping by 12%. 

Christopher D. Carroll, Principal Deputy Assistant Secretary at SAMHSA, said the findings suggest encouraging progress across several behavioral health measures. He added that young adults and adolescents have continued to show either improving or stable patterns in many key indicators during the last five years. 

The latest federal data aligns with research produced by other organizations, including the University of Michigan and the Centers for Disease Control and Prevention. Those studies have also found that marijuana use among younger Americans has reached historically low levels. 

In addition, an analysis published by the Marijuana Policy Project in 2025 concluded that youth cannabis consumption has fallen across nearly every state where recreational cannabis has been legalized. 

While younger age groups are reporting reduced cannabis use, the picture is different for older Americans. Federal survey results indicate that adults aged 26 and above have shown increasing levels of self-reported cannabis use in recent years, with the largest growth occurring among older age groups. 

Responding to the new figures, NORML’s Paul Armentano argued that the data challenges claims that legal recreational marijuana policies encourage greater use among teenagers. He said the findings demonstrate that carefully regulated cannabis laws can provide legal access for adults without leading to increased use among young people, adding that the results should give policymakers greater confidence when considering cannabis regulation. 

As states legalize some form of marijuana use and allow companies like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) to operate, measures like age-verification conducted at dispensaries help to reduce the number of teens that access marijuana, hence triggering a reduction in self-reported marijuana use. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Idaho MMJ Initiative Fails to Qualify for November Ballot

Idaho voters will not have the opportunity to decide on a proposed medical cannabis measure during the upcoming November election after state officials ruled that the initiative failed to satisfy legal qualification standards. 

The decision was announced by the Idaho Secretary of State’s Office, which determined that the proposed Idaho Medical Cannabis Act Initiative didn’t collect enough valid support to earn a place on the statewide ballot. 

According to a letter sent to the Natural Medicine Alliance of Idaho (NMAI), the organization leading the campaign, the petition effort failed to meet several statutory requirements established under Idaho election law. 

To qualify for the ballot, supporters were required to collect signatures from at least 6% of registered voters in 18 of Idaho’s 35 legislative districts. Overall, the campaign also needed approximately 70,000 valid signatures statewide. State officials reported that organizers submitted about 58,000 signatures and reached the required threshold in only 13 legislative districts, leaving the proposal well below the necessary benchmark. 

The Secretary of State’s office also identified additional concerns discovered during the review process. Among them was a signature associated with an individual who had died about five years ago. Officials further found signatures connected to people whose voter registrations had previously been removed from the state’s records. 

The review also uncovered issues involving campaign documentation and financial reporting. In addition, the officials said they could not verify the Idaho residency of 293 petition circulators. Under state law, only Idaho residents are permitted to collect signatures for ballot initiatives. 

The letter stated that the shortage of qualifying signatures at both the statewide and legislative district levels was, by itself, enough to reject the filing. It added that the other findings only reinforced the decision and were not needed as separate grounds for disqualification. 

The NMAI responded in an emailed statement, saying it conducted the campaign honestly and intends to cooperate with any official review. The organization explained that it hired a professional signature-gathering company because its members lacked experience managing a statewide petition drive. It said the group relied on that firm to complete the work in accordance with Idaho law while maintaining confidence in the state’s established ballot initiative process. 

The organization said its mission was driven by the belief that people living with severe and chronic medical conditions should have access to alternatives to prescription opioid medications. It also argued that Idaho residents should have the freedom to make personal healthcare choices without unnecessary government interference. 

Campaign finance filings show the organization spent approximately $2.7 million in its unsuccessful effort to place the proposal before Idaho voters this November. Medical marijuana firms around the country, such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), will be disappointed that patients in Idaho will have to wait longer before they can legally access medical marijuana products to manage their symptoms. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Massachusetts Marijuana Prohibitionists Survive Lawsuit, Petition Remains

A legal effort to overturn Massachusetts’ adult-use cannabis framework cleared a significant hurdle after the state’s highest court upheld the petition process, keeping it on track for a possible appearance on the November 2026 ballot. 

The Massachusetts Supreme Judicial Court determined on June 12 that state AG Joy Campbell acted within her authority when she certified, in September 2025, a ballot proposal that seeks to dismantle the state’s recreational marijuana system, a market valued at about $1.6 billion and approved by voters in 2016 with 54% support. 

The campaign, led by the Coalition for a Healthy Massachusetts, cleared the first signature-gathering stage after submitting 74,574 verified signatures in December. Organizers must now collect an additional 12,429 signatures from registered voters by next month. The requirement came after state lawmakers chose not to advance the proposal during the legislative review process. 

Four voters tried to stop it, claiming multiple subjects and an unfair summary lacking mention of social equity trust fund elimination and alleged uncompensated taking. 

The challenge asserted that the petition combined unrelated policy areas and that the official summary failed to fairly describe impacts, particularly the removal of programs supporting equity funding, which they argued could constitute an unlawful taking. 

The court disagreed, with Justice Elizabeth N. Dewar writing that the certification met constitutional requirements and that the summary adequately reflected the measure’s scope, sending the matter back to a lower court for final judgment. 

It would repeal chapters 94G and 64N, ending rules governing retail sales, cultivation, possession framework, and taxation of nonmedical cannabis, while preserving the legal right for adults to grow up to six plants at home. 

It would leave medical marijuana laws intact and would not reinstate criminal penalties for adults 21 and older holding up to one ounce of marijuana or five grams of concentrate, though smaller violations would still face civil fines. 

It would introduce mandatory drug education and community service requirements for younger offenders and create an expedited route for existing recreational businesses to transition into the medical cannabis sector. 

The plaintiffs argued that the medical and recreational frameworks are separate policy areas and that removing requirements such as host community agreements and adding youth penalties placed unrelated elements into a single proposal. 

The court concluded that all provisions share a unified objective of tightening controls on recreational cannabis rather than advancing unrelated policy goals. 

The justices also found the attorney general’s summary sufficiently clear, noting it conveyed the central effect of the measure while pointing out that voters receive additional explanatory materials prepared by Secretary of the Commonwealth William Galvin. 

Recent polling indicated the proposal faces significant resistance, with about 63% of respondents opposing repeal and roughly 20% expressing support. 

The developments in Massachusetts will be closely watched by the marijuana movement, including enterprises like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), because the ballot measure could trigger similar steps to be taken in other legal marijuana markets in years to come. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Chicago Class-Action Lawsuit Alleges Deceptive Advertising of Medical Marijuana Products

A newly filed federal class-action lawsuit is raising questions about how cannabis products are promoted in the U.S., with plaintiffs arguing that some of the industry’s largest companies have misled consumers about both benefits and potential health risks. 

The case, submitted in federal court in May, targets three Chicago-based cannabis operators: Verano Holdings, Cresco Labs, and Green Thumb Industries. Spanning over 300 pages, the complaint alleges the companies presented cannabis products as effective for a wide range of medical and psychological conditions while failing to adequately communicate possible adverse effects. 

According to the lawsuit, the businesses promoted cannabis as a remedy for issues such as chronic pain, anxiety, sleep disorders, and certain autoimmune conditions, despite the fact that cannabis has not received approval from the FDA for those treatments. 

The filing describes what it calls a coordinated industry effort to market products containing high levels of THC, the primary psychoactive component in cannabis. Attorneys representing the plaintiffs argue that marketing campaigns have emphasized therapeutic claims while minimizing concerns about potential harm. 

The lawsuit references multiple scientific studies examining the effects of cannabis use. Among them is a 2017 NASEM report that identified evidence linking marijuana consumption to an increased likelihood of schizophrenia and other psychotic disorders, particularly among frequent users. 

Patrick Kenneally, an attorney with Burke Law Group representing the plaintiffs, said clearer warnings are needed so consumers can make informed purchasing decisions. He argued that some users experiencing mental health or physical problems may not recognize a possible relationship between those issues and their cannabis consumption. 

Kenneally also compared the current debate surrounding marijuana to public discussions about tobacco decades ago, before widespread awareness campaigns and health warnings became common. He said greater public education, whether through labels, packaging inserts, or in-store notices, is necessary to ensure consumers understand potential risks. 

The lawsuit also alleges financial injury, claiming customers may have paid premium prices or bought products they otherwise would have avoided if more complete information had been available. 

Verano Holdings responded in a statement, noting that it is part of a broader legal campaign against multi-state marijuana operators and noting that similar claims have previously been dismissed by courts. The company stated that it complies with state regulations governing testing, labeling, and consumer warnings. 

Verano also pointed to recent federal actions and long-standing state medical marijuana programs as evidence of official recognition of cannabis’s medical uses. The company said it intends to contest the allegations in court. 

Kenneally, who noted he was not involved in the lawsuits cited by Verano, said the legal battle could take several years to resolve. 

This case is likely to be followed by companies like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and other licensed marijuana companies that make and sell medical marijuana products in the U.S. as its outcome could impact the trajectory of the industry. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New York Cannabis Social Equity Entrepreneurs Stuck As State Support Underwhelms

When New York legalized recreational marijuana in 2021, it framed the move as a step toward restorative justice, promising an industry that would benefit communities most harmed by prohibition. 

A central piece of that plan was the Conditional Adult-Use Retail Dispensary (CAURD) program, designed to give retail licenses to individuals with prior cannabis-related convictions. The idea was that those most impacted by decades of enforcement would be first in line to take part in the legal market. 

Applicants followed state requirements, completed training, submitted paperwork, and waited through delays while investing personal savings to prepare for opening. 

Later, the state launched a $200 million Social Equity Cannabis Investment Fund through the Dormitory Authority of the State of New York (DASNY) to provide low-interest financing for leases and construction. 

In practice, buildouts were routed through state-approved vendors, and costs often escalated beyond expectations, leaving operators with limited control over key decisions. 

Financing structures involved private partners, including Chicago Atlantic, a real estate investment trust active in cannabis lending, which helped shape loan terms tied to these projects. 

As a result, many license holders entered operations carrying multi-million-dollar debt burdens in a market that was shifting faster than projections anticipated. 

One example is Stoops, a cannabis retail shop in Manhattan’s Flatiron District built as a neighborhood-focused store emphasizing education, compliance, and community engagement. The business model included local hiring, tax compliance, and strict adherence to regulatory rules. 

Despite these efforts, operators have faced mounting pressure from falling marijuana prices and ongoing competition from an unlicensed market that continues to operate across the state. Additionally, some CAURD operators tied to DASNY and Chicago Atlantic financing face repayment terms that no longer match market reality. 

What was meant to be a path to ownership and repair has, for many, become a financial strain that threatens the survival of the entrepreneurs the program was designed to support. 

These concerns contributed to the formation of CAURD Inc., a member-led organization composed of early CAURD license holders seeking coordinated advocacy. The group is calling for restructuring or partial relief of state-backed loans, greater transparency in how construction costs and interest rates were determined, increased flexibility in vendor selection, and improved access to working capital to stabilize legal operators. 

Advocates argue that while regulatory oversight remains important, financial burdens tied to the program’s design should not fall disproportionately on small businesses that entered the market under the promise of economic justice and restorative opportunity. 

Operating in the state-legal marijuana industry has always been challenging, and even well-established firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are grappling with operational challenges linked to the regulatory systems in the jurisdictions where they have operations. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Medical Marijuana Could Expand as Feds Reschedule the Drug

A recent federal decision to reclassify medical cannabis is reshaping the outlook for licensed operators, prompting renewed attention from businesses and regulators across the country. 

The change, introduced under an order signed by Acting Attorney General Todd Blanche, moves state-approved medical cannabis to Schedule III of the CSA. That adjustment carries significant financial implications, particularly when it comes to taxation. 

Beginning in the first quarter of 2026, companies operating in the medical marijuana space will be allowed to deduct ordinary business expenses. This marks a sharp departure from previous restrictions that fell under Section 280E of the Internal Revenue Code, which has long prevented cannabis businesses from claiming such deductions. 

According to data from analytics firm Headset, the average dispensary could save around $268,000 annually under the new classification. For many businesses that have struggled to remain profitable, those savings could shift the balance, turning losses into gains. 

Recreational marijuana operators, however, remain subject to those rules for now, creating a split in how the industry is taxed. These operators are awaiting the outcome of a fast-tracked administrative review scheduled to begin June 29 and wrap up by mid-July. 

The process will determine whether they might also benefit from relief tied to Section 280E. Until then, operators and regulators are weighing their options. 

Some states are already moving ahead. In California, officials have introduced a simplified system that allows cannabis businesses to modify their license type without waiting for renewal. The Department of Cannabis Control said the change is intended to speed up approvals and reduce administrative hurdles. Businesses can now shift to a medical designation or add one alongside an existing adult-use license with fewer requirements. 

The policy shift comes as California’s once-dominant medical marijuana market has sharply declined. Sales that exceeded $2.5 billion in 2017 dropped to below $185 million by 2025. Industry observers point to high taxes, registration costs, and limited product access as factors that have driven patients elsewhere. Many have either turned to unregulated sellers or opted to purchase through adult-use channels despite having medical needs. 

The new federal classification may encourage businesses to refocus on serving medical patients, given the financial advantages now tied to that segment. It could also prompt regulators to expand access to medical licenses, particularly in states where those permits are currently concentrated among large, well-funded operators. 

In New Jersey, where recreational sales launched in 2022 through existing medical providers, regulators may consider allowing more businesses to enter the medical market. Industry consultants say discussions are already underway, though officials are still evaluating how best to respond to the evolving federal framework. 

Other states may take broader approaches. Some could consider redefining their entire cannabis market as medical in order to extend tax benefits to all licensed operators. Washington, D.C. offers a notable example. Although voters approved recreational marijuana in 2014, federal restrictions have prevented the city from establishing a traditional retail system for recreational sales. 

As a workaround, leaders created a system that allows adults over 21 to register as medical patients without a physician’s recommendation, enabling them to purchase cannabis legally through licensed dispensaries. 

The model could gain traction elsewhere if states look for ways to align with federal policy while supporting local businesses. 

Meanwhile, debate continues at the national level. Critics, including some lawmakers, argue that more research is needed on the health effects of cannabis before further regulatory changes are made. 

The evolving regulatory climate at the federal level is going to be closely watched by medical cannabis firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF). 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Sales Record Major Spike on 4/20

Cannabis retailers across the U.S. recorded a notable surge in sales on April 20 (4/20) this year, with particularly strong gains in states that have recently approved legal use. 

Data released by online ordering company Jane Technologies shows that total sales on April 20 climbed by 46.9% compared to the same date last year. The number of transactions also rose sharply, increasing by 46.6%. The figures reflect activity from stores that were operating in both 2025 and 2026, a method the company used to avoid overstating growth due to newly opened locations. 

Socrates Rosenfeld, co-founder and chief executive of Jane Technologies, said the yearly spike offers insight into broader trends shaping the market. He noted that demand continues to expand as more states embrace legalization. He added that businesses focusing on improving the customer experience are gaining a competitive edge. 

Retailers saw a significant jump in daily traffic as well, with transactions on April 20 rising 73% compared to the previous day. 

At the state level, performance varied. Illinois posted the strongest results, leading all markets with a 44.5% increase in sales compared to last year. California, the nation’s largest cannabis market, recorded a 25.8% gain. Maryland followed with a 31.5% increase. In contrast, some established markets experienced slight declines. Nevada saw sales dip by 2.7%, New Jersey by 1.1%, and Colorado by 7.1%. 

Minnesota reported a dramatic 150% rise in sales, though analysts caution that the figure is influenced by the state’s recent shift to recreational marijuana, which began late last year. 

Product preferences remained largely consistent with previous trends. Traditional marijuana flower accounted for the largest share of purchases, making up 43% of total sales. Vape products followed at 27%, while edibles represented 14%. Pre-rolled products captured 10%, and concentrates and extracts made up the remaining 6%. 

Despite the positive results tied to April 20, the broader market picture is more complex. In California, for example, total annual cannabis sales reached $3.9 billion last year, down from $4.2 billion in 2024. This suggests that while peak events drive strong short-term gains, the industry continues to face challenges. 

Rosenfeld added that the sector is evolving rather than slowing down. He pointed to increasing competition and changing consumer expectations as signs of a maturing market. According to him, companies that focus on long-term strategies are likely to benefit as the industry develops further. 

Meanwhile, data from marijuana analytics firm Lit Alerts indicates that 4/20 does not rank among the top ten sales days in several states, including Missouri, New York, Ohio, New Jersey, Maryland, and Massachusetts. 

That particular insight is a matter that cannabis firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) will analyze in order to establish any lessons that can guide their future strategies. 

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN